GMAB - Genmab: Recent Updates Support The Growth Narrative

2024-02-21 03:44:55 ET

Summary

• Genmab's 2023 annual report shows strong financial performance and continued clinical success, setting the company up for growth in 2024.
• The company's pipeline includes promising candidates and collaborations with industry giants, supporting future growth.
• Risks to consider include legal disputes and competition, but overall, Genmab's growth narrative remains intact.

It has only been a little over a month since my last Genmab A/S ( GMAB ) article , where I discussed three trends that I believe investors need to track over 2024. I stressed how important it was for the global biotech juggernaut, to show growth from EPKINLY (epcoritamab) and Darazalex, as well as continue to keep the pedal down with their pipeline efforts. Although I still believe those trends are key in 2024, I wanted to point out how the company’s Annual Report for 2023 has indicated that Genmab is capable of achieving those goals and supports the company’s growth narrative....

For further details see: